Radioactive microspheres aim to shrink stubborn liver tumors
NCT ID NCT07657273
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a treatment called NRT6003, which delivers tiny radioactive beads directly to liver tumors through a blood vessel. It is for people with liver cancer that has already been treated but not cured. The goal is to see if this single session of internal radiation can safely shrink tumors and control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NRT6003 (yttrium-90 carbon microspheres)
What this could lead to
If it works, this could offer a new way to control liver tumors that haven't responded to earlier treatments, potentially shrinking them and improving outcomes.
What could go wrong
This is a small, early-phase study with only 20 people, so results may not apply widely. The treatment involves radiation and could cause side effects like liver damage or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital, Guangzhou Medical University
Guangzhou, Guangdong, 510260, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact